NASDAQ:LMNX - Luminex Stock Price, Forecast & News

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex declared a quarterly dividend on Tuesday, February 18th. Stockholders of record on Thursday, March 19th will be paid a dividend of $0.09 per share on Thursday, April 9th. This represents a $0.36 annualized dividend and a dividend yield of 1.45%. The ex-dividend date of this dividend is Wednesday, March 18th. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) posted its quarterly earnings results on Monday, February, 10th. The medical instruments supplier reported $0.07 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.08. The medical instruments supplier earned $90.50 million during the quarter, compared to analysts' expectations of $90.27 million. Luminex had a negative return on equity of 2.03% and a negative net margin of 1.18%. Luminex's quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.04 EPS. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Luminex.

Luminex issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, February, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $82-84 million, compared to the consensus revenue estimate of $87.74 million.

3 brokerages have issued twelve-month price targets for Luminex's stock. Their forecasts range from $21.00 to $32.00. On average, they expect Luminex's stock price to reach $26.50 in the next year. This suggests a possible upside of 7.0% from the stock's current price. View Analyst Price Targets for Luminex.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Headlines about LMNX stock have been trending very negative recently, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Luminex earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Luminex.

Luminex saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 1,400,000 shares, an increase of 5.3% from the January 30th total of 1,330,000 shares. Based on an average trading volume of 268,300 shares, the short-interest ratio is presently 5.2 days. Currently, 3.4% of the shares of the company are sold short. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Cambrex (CBM), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include AbbVie (ABBV), Pfizer (PFE), Baidu (BIDU), Micron Technology (MU), Verizon Communications (VZ), Gilead Sciences (GILD), Alphabet (GOOG), Nektar Therapeutics (NKTR), Starbucks (SBUX) and Canopy Growth (CGC).

Luminex's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.10%), State Street Corp (2.87%), Investment Management of Virginia LLC (2.05%), Geode Capital Management LLC (1.33%), Bank of New York Mellon Corp (1.33%) and Bank of America Corp DE (0.96%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, THB Asset Management, Martingale Asset Management L P, Russell Investments Group Ltd., AQR Capital Management LLC, Skandinaviska Enskilda Banken AB publ , Bessemer Group Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Luminex.

LMNX stock was acquired by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, California Public Employees Retirement System, Goldman Sachs Group Inc., Eos Focused Equity Management L.P., Aviva PLC, State Street Corp, Bank of Montreal Can and Renaissance Technologies LLC. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II and Nachum Shamir. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $24.76.

Luminex has a market capitalization of $1.12 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

The official website for Luminex is http://www.luminexcorp.com/.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]